INTRODUCTION
Clear guidelines exist for the prevention of infections in patients undergoing hematopoietic stem cell transplantation (HSCT), (1)(2) but there is no guidance regarding prophylactic antimicrobial therapy for pediatric cancer patients receiving systemic chemotherapy. Infection, whether due to bacterial, fungal, viral, or parasitic pathogens, is a leading cause of morbidity and mortality in this patient population. (3)( 4)( 5) For example, more than 60% of children being treated for acute myeloid leukemia (AML) experienced at least 1 microbiologically documented infection during therapy, and the cumulative infectious mortality rate was 11%. (5) Therefore, infection prevention is of the utmost importance. Due to the lack of standard guidelines for infection prevention in most children being treated for cancer, current strategies often vary among institutions. In this article, we focus on our infection prophylaxis approach at an urban academic medical center for bacterial, fungal, viral, and parasitic infections as well as vaccination strategies for pediatric oncology patients undergoing treatment with systemic chemotherapy.
ANTIBACTERIAL PROPHYLAXIS

General Principles
Bacterial infections remain a common and potentially lifethreatening complication of childhood cancer therapy. Several factors predispose the children to infectious complications. Certain malignancies are inherently associated with immune deficits. Patients with hematologic malignancies may have leukopenia due to infiltration of the marrow with malignant cells. Chemotherapy administration often results in neutropenia, which is defined as an absolute neutrophil count (ANC) (mature granulocytes þ neutrophil band cells) of less than 500/mL (0.5 Â 10 9 /L). When children have neutropenia, they are at increased risk of infection, with the probability of infection directly related to the severity and duration of neutropenia. (6) Chemotherapy can also impair innate and acquired immune responses and disrupt physical immune defenses, such as the gut mucosal barrier, producing an additive negative effect on the protective immune response. Children younger than age 2 years are especially vulnerable to infections because the detrimental effect of cytoreductive therapy is superimposed on a developing, age-dependent immature immune system.
The standard of care for the febrile neutropenic patient is clearly described in guidelines written by national organizations such as the Infectious Diseases Society of America (IDSA), Centers for Disease Control and Prevention (CDC), and the National Comprehensive Cancer Network (NCCN).
(2)(7) In more than 50% of cases of febrile neutropenia, no microbiologic source is identified. The most commonly identified clinical syndromes are bloodstream infections (often related to a break in the mucosal border or to a central venous catheter), respiratory infections, and skin and mucosal infection. Gram-positive organisms presently account for 66% of bacteremias. Low-virulence, coagulasenegative Staphylococcus species and viridans group streptococci are commonly recovered. Other commonly isolated Gram-positive organisms include a-hemolytic streptococci, enterococci, and Streptococcus pneumoniae. Gram-negative organisms such as Escherichia coli, Pseudomonas species, and Klebsiella species are identified in approximately 33% of patients with bacteremia, fever, and neutropenia.
Although fever and neutropenia are common in children undergoing cancer treatment, prophylactic antibiotic therapy for nonfebrile neutropenic patients is not routinely recommended in national guidelines. In contrast, guidelines from the IDSA and the NCCN recommend use in adult patients who have high-risk cancers. (2)(8) In most centers treating adults with malignancies, a fluoroquinolone is the agent of choice for prophylaxis because of its broad coverage of both Gram-negative (including Pseudomonas) and Grampositive bacteria. A recent meta-analysis of 95 randomized, controlled trials of prophylaxis for adult afebrile neutropenic oncology patients showed a significantly decreased risk of death in those receiving prophylaxis, with the most benefit (33% decreased risk) from fluoroquinolones. (9)
Antibacterial Prophylaxis in Children with Severe and Prolonged Neutropenia
Theoretically, prophylactic levofloxacin could prevent morbidity and possibly mortality in children with severe (ANC <100/mL [0.1 Â 10 9 /L]) and prolonged (>7 days) neutropenia associated with chemotherapy. Currently, fluoroquinolones are recommended as prophylaxis only for children undergoing allogeneic HSCT. (1)(2) For other high-risk cancers, such as AML, where the risk of serious infection is associated with mortality in the range of 6.9% to 11%, clear recommendations do not exist. (5)(10) Recurrent acute lymphoblastic leukemia (ALL) also carries a significant risk of severe infection. One Children's Oncology Group (COG) study in children with relapsed ALL reported rates of febrile neutropenia and clinically or microbiologically documented infections at 59.7%, 39.6%, and 79.4%, respectively, per block of therapy. (11) Subsequently, small studies have found substantially reduced rates of infections in children with AML and ALL who received antibiotic prophylaxis. (12)(13) (14)(15) Fluroquinolones levofloxacin and ciprofloxacin have similar gram-negative coverage, but levofloxacin may have broader gram-positive coverage, especially against viridans streptococci, a common cause of invasive disease in children with neutropenic mucositis. (7) An ongoing, randomized COG trial (NCT01371656) investigating the use of prophylactic therapy with levofloxacin in patients being treated with intensive chemotherapy for acute leukemia and those undergoing HSCT will determine the effect of bacterial prophylaxis on incidence of bacteremia as well as evaluate resistance patterns, antibiotic use, adverse effects, and C difficile infection rates in these at-risk populations.
Some centers recommend levofloxacin prophylaxis for afebrile patients with severe and prolonged neutropenia to prevent systemic bacterial infection and to decrease the overall incidence of hospitalization due to fever. Such patients include those with recurrent ALL, or AML and autologous HSCT recipients ( Table 1) . Among the potential benefits of using levofloxacin for severe and prolonged neutropenia are prevention of a significant infection, which has inherent risks of morbidity and mortality, and avoidance of chemotherapy delays, which could contribute to increased risk of disease recurrence. Moreover, cost analysis studies have shown that antibiotic prophylaxis in severe and prolonged neutropenia in both adults and children is substantially less expensive than treating bloodstream infections. (15)(16) A small retrospective study on children with AML found that patients receiving prophylaxis with ciprofloxacin had significantly less infections caused by gram-negative bacteria but an increase in viridans streptococci than the patients who had not received prophylaxis. (17) A theoretical risk of using levofloxacin is the selection of resistant bacteria. To date, no studies in children or adults have shown an increased rate of infection with resistant organisms, (17) but some studies suggest an increased rate of colonization with resistant organisms. (18) For this reason, it is prudent for each institution to implement a systemic strategy for monitoring the development of fluoroquinolone resistance among Gram-negative bacilli. In addition, patients should be monitored for adverse effects related to levofloxacin, including nausea, diarrhea, headache, and dizziness. Tendonitis and tendon rupture are estimated to have an incidence range of 0.14% to 0.4% and are more commonly associated with age older than 60 years and coadministered corticosteroid use. (19) A trial in 2500 children, 50% of whom received levofloxacin, reported slightly higher rates of arthralgia (2.1%) in the levofloxacintreated group when compared to the control group (0.9%). (20)
Prophylaxis Against Mycobacterium tuberculosis
All children should undergo a screening test for latent M tuberculosis infection before initiation of immunosuppressive therapy. As per American Academy of Pediatrics (AAP) recommendations, any child with a tuberculosis risk factor who will receive an immunomodulating biologic agent should have both an interferon-g release assay (IGRA) and purified protein derivative (PPD) skin test performed before therapy initiation (Table 1) . (21) A positive PPD skin test (defined by risk factors and millimeters of induration) or IGRA should be followed up with a chest radiograph to determine if there is active tuberculosis (TB). All asymptomatic children with a positive PPD or IGRA result and negative chest radiograph (thereby meeting the definition of latent TB) should receive isoniazid prophylaxis for 9 months, which should be initiated before chemotherapy. (22)(23) Children with active TB should begin treatment with at least 3 anti-TB medications before beginning chemotherapy. Because these medications may interact with chemotherapeutic agents and cause hepatotoxicity, clinicians should consult with a pediatric infectious diseases or pulmonology specialist.
Prophylaxis Against Clostridium difficile in Children with Prior C difficile Infection
An estimated 25% of all pediatric cases of C difficile infection occur in children who have underlying malignancies, and 5% of children with cancer develop C difficile infection during their multiple hospitalizations. (24)(25)(26)(27) One study found that approximately 33% of pediatric oncology patients tested upon hospital admission were colonized with C difficile, as indicated by a positive polymerase chain reaction test in the absence of gastrointestinal symptoms, and more than 50% remained colonized upon retesting 20 weeks later. (28) Moreover, the recurrence rate of C difficile infection is about 30%. (29) Given the high prevalence of C difficile colonization and infection in the pediatric oncology population as well as the strong chance of recurrence, our institutional guidelines suggest "secondary prophylaxis" with oral vancomycin for children with a history of C difficile infection who are receiving systemic antibiotics (Table 1) . Oral vancomycin could be continued for the duration of receipt of systemic antibiotics and up until 3 to 7 days after discontinuation of the systemic antibiotics. Although evidence supporting this practice is scant and randomized, controlled trials are lacking, recent literature supports this approach. (30)(31)
ANTIFUNGAL PROPHYLAXIS
General Principles
Fungal infections are increasing in incidence among pediatric patients with cancer due to aggressive chemotherapeutic and immunosuppressive regimens, the use of broad-spectrum antibiotics and corticosteroids, and prolonged neutropenia. (32)(33) Previous studies have reported a 5% to 7% incidence of fungal infections in children with hematologic and oncologic malignancies, with a mortality rate of up to 60%, depending on the fungus. (32)(33)(34)(35)(36)(37) 
Acute lymphoblastic leukemia (ALL)
High risk (current or expected prolonged severe neutropenia [<100/mL {0.1 Â 10 9 /L} for >7 days]): Bacterial: Levofloxacin* • >6 mo to £4 y: 10 mg/kg per dose IV/PO every 12 h (maximum daily dose 500 mg).
• ‡5 y: 10 mg/kg per dose IV/PO every 24 h (maximum daily dose 750 mg).
• Continue until ANC >200 /mL (0.2 Â 10 9 /L) and rising following nadir.
• Levofloxacin should be discontinued if patient requires broad-spectrum antimicrobials for fever/ neutropenia. Fungal:
• Fluconazole 6 mg/kg (maximum 400 mg) IV/PO every 24 h.
All ALL patients:
Viral:
• HSV seropositive or previous HSV infection: acyclovir* 250 mg/m 2 per dose IV every 8-12 h or valacyclovir* 15-20 mg/kg per dose (maximum 500 mg/dose) PO every 12 h.
• VZV: Postexposure prophylaxis with VZIG or acyclovir 500 mg/m 2 per dose IV every 8 h*. Ensure family is immunized.
• Influenza: Children and household members older than 6 mo should receive trivalent inactivated influenza vaccine. If close contact to individual is known to have influenza, provide postexposure chemoprophylaxis with oseltamivir* for no more than 10 days.
• RSV: Infants (November-March): palivizumab 15 mg/kg per dose IM once monthly • Hepatitis B infection: Age-dependent treatment regimen. Contact pediatric infectious diseases or gastroenterology specialist. Pneumocystis:
• Trimethoprim-sulfamethoxazole* # at a dose of trimethoprim 5 mg/kg per day divided BID 2-3 consecutive days per week. • Initiate after completion of induction and continue until 3-6 months after therapy completion. Parasitic:
• If patient has lived or travelled to an endemic region (tropics, Southeast Asia), obtain serology to rule out Strongyloides PRIOR to initiating chemotherapy.
• Measure Toxoplasma gondii IgG to determine latent infection. Treat with trimethoprimsulfamethoxazole if positive (should be administered already to prevent PCP).
Mycobacterial:
• If patient has risk factor for Mycobacterium tuberculosis exposure, before initiating chemotherapy, place PPD in children <5 y and perform IGRA in children ‡5 y. If positive, obtain pediatric infectious disease or pulmonology consultation. Clostridium difficile • Patients with prior C difficile infection should be offered oral vancomycin 10 mg/kg (maximum 125 mg) every 12 h when placed on antibiotics. IgG levels may be monitored throughout treatment. If IgG values are less than normal for age, IVIg at 400 mg/kg may be administered.
Acute Myeloid Leukemia
Bacterial: Levofloxacin* • >6 mo to £4 y: 10 mg/kg per dose IV/PO every 12 h (maximum daily dose 500 mg).
• Continue until ANC >200 /mL (0.2 Â 10 9 /L) and rising following nadir or day 60 if ANC >200/mL (0.2 Â 10 9 /L) is not reached.
• Levofloxacin should be discontinued if patient requires broad-spectrum antimicrobials for fever/neutropenia. Fungal:
• Fluconazole 6 mg/kg (maximum 400 mg) IV/PO every 24 h. Viral:
• HSV seropositive or prior HSV infection: acyclovir* 250 mg/m 2 per dose IV every 8-12 h or valacyclovir* 15-20 mg/kg per dose (maximum 500 mg/dose) PO every 12 h.
• VZV: Postexposure prophylaxis with VZIG or acyclovir*. Ensure family is immunized.
• RSV: Infants (November-March): palivizumab 15 mg/kg per dose IM once monthly.
• Hepatitis B infection: Age-dependent treatment regimen. Contact pediatric infectious diseases or gastroenterology specialist. Pneumocystis:
• Trimethoprim-sulfamethoxazole* # at a dose of trimethoprim 5 mg/kg per day divided BID 3 consecutive days per week. • Initiate with induction and continue until 3-6 mo after therapy completion. /L}] for >7 d): Bacterial: Levofloxacin* • >6 mo to £4 y: 10 mg/kg per dose IV/PO every 12 h (maximum daily dose 500 mg).
• Continue until ANC >200/mL (0.2 Â 10 9 /L) and rising following nadir or day 60 if ANC >200/mL (0.2 Â 10 9 /L) is not reached.
• Fluconazole 6 mg/kg (maximum 400 mg) IV/PO every 24 h (initiate Day þ1 and continue until engraftment). Viral:
• HSV seropositive or prior HSV infection: acyclovir* 250 mg/m 2 per dose IV every 8 h or valacyclovir* 15-20 mg/kg per dose PO every 12 h (initiate Dayþ1 and continue until day of discharge).
• VZV: Post exposure prophylaxis with VZIG or acyclovir*. Ensure family is immunized.
• Trimethoprim-sulfamethoxazole* # at a dose of trimethoprim 5 mg/kg per day divided BID 2 consecutive days per week. • Dapsone, check glucose-6-phosphate dehydrogenase before administration species are normal colonizers of mucosal and skin surfaces, mucositis places patients at higher risk for Candida infections. At-risk populations include patients undergoing allogeneic or autologous HSCT, those with AML or relapsed ALL, and patients who have an anticipated duration of neutropenia of more than 7 days. (38) We currently recommend antifungal prophylaxis for each of these at-risk groups at our institution.
Fluconazole, a triazole medication that interferes with the fungal cytochrome P450 activity, provides coverage against many Candida species, although innate resistance exists against C glabrata and C krusei. Fluconazole also lacks coverage for Aspergillus. Two meta-analyses suggested that antifungal prophylaxis should be used in patients with severe, prolonged neutropenia based on findings of fewer invasive fungal infections and less fungal-related mortality in those who had received fluconazole. Currently, broader antifungal agents have failed to show benefit over fluconazole. Recent published guidelines continue to recommend fluconazole prophylaxis in patients with severe and prolonged neutropenia. (38)(40) The ongoing COG trial (NCT01307579) investigating the efficacy of caspofungin acetate, an echinocandin, compared with fluconazole in preventing invasive fungal infections in children with AML undergoing chemotherapy should provide valuable insight into potentially broadening antifungal coverage in this population. Voriconazole, another triazole medication, should be considered for patients who are at risk for Aspergillus infections, such as those with possible environmental exposures (eg, dust from recent construction or exposure to faulty ventilation systems) or patients receiving vinca alkaloids to avoid neurotoxicity due to cytochrome P450 inhibition.
Outside of these indications, fungal prophylaxis is not routinely recommended, although individual practitioners often prescribe fluconazole for patients receiving high-dose corticosteroid therapy.
If empiric treatment for an invasive fungal infection is required in a patient who is receiving prophylactic fluconazole, we recommend initially increasing the fluconazole to treatment dosing levels. If the patient does not experience clinical improvement, fungal coverage should be broadened to an echinocandin, voriconazole, or amphotericin B.
Pneumocystis (jiroveci [carinii]) Pneumonia (PCP) Prophylaxis
PCP is an opportunistic fungal infection that affected approximately 40% of children with cancer before antibiotic prophylaxis. (41) PCP infection in non-human immunodeficiency virus (HIV)-infected patients is characterized by fever, dry cough, hypoxia, and shortness of breath, which can progress to fulminant respiratory failure. Colonization with P jiroveci is widely observed in the general population, and most children acquire serologic response in early childhood. (8) PCP prophylaxis is necessary for all children being treated for hematologic malignancies, such as lymphoma or leukemia (Table 2) . Patients receiving the immunosuppressive regimens listed in Table 3 require prophylaxis. The primary regimen for PCP prophylaxis is trimethoprim (TMP)-sulfamethoxazole (SMX) administered 2 to 3 consecutive days per week, which has been recommended in several guidelines by major organizations. (2)(42)(43) A meta-analysis of 13 randomized controlled trials involving 1,412 immune compromised non-HIV infected patients showed TMP-SMX significantly reduced PCP-related mortality (OR 0.17, 95% CI 0.03-0.94). (44) TMP-SMX prophylaxis was associated with a 91% reduction in the occurrence of PCP (RR 0.09, 95% CI 0.02-0.32) in a subgroup analysis; included within this review were 520 children with ALL. Myelosuppression is a common adverse event caused by TMP-SMX prophylaxis, and no difference in efficacy has been found in reducing weekly doses to either 2 consecutive days per week (45)(46)(47) or a single day per week. (48)(49) For patients who cannot tolerate TMP-SMX, alternative regimens used for PCP prophylaxis in non-HIV-infected patients include intravenous or aerosolized pentamidine, atovaquone, and dapsone with or without pyrimethamine. Pentamidine has both antifungal and antiparasitic activity. Although the exact mechanism of action is not yet defined, it is believed to inhibit microbial enzymes as well as the oxidative phosphorylation of protozoan DNA, RNA, protein, and phospholipids. When delivered intravenously, the blood pressure, glucose, electrolytes, and liver and renal function of the patient should be monitored. Aerosolized pentamidine provides efficacy similar to that achieved with intravenous administration with less systemic adverse effects (although this method requires specific medication handling). When administering aerosolized pentamidine, the patient should be premedicated with a bronchodilator (albuterol) to avoid pentamidine-induced bronchospasm. Despite minimal hematologic and severe toxicities, atovaquone is rarely used as prophylaxis because most children do not tolerate the unpleasant taste. Dapsone (with or without pyrimethamine) is also a reasonable alternative, but this agent is significantly more expensive than the other regimens, and there are theoretical concerns of methemoglobinemia in individuals with glucose-6-phosphate dehydrogenase deficiency along with other hematologic toxicities. Of note, a recent casecontrol study in HCT recipients failed to identify any hematologic toxicity with dapsone among patients allergic to TMP-SMX. (47) In nonallogeneic HSCT recipients, PCP prophylaxis should continue until 3 to 6 months after completion of chemotherapy.
ANTIVIRAL PROPHYLAXIS
Viral infections during childhood are common, and primary management includes prevention of exposure by hand hygiene, vaccination, and isolation of infected patients and exclusion of infected health-care workers. Most viral infections in pediatric oncology patients are mild respiratory infections. Those who have neutropenia may display more severe symptoms with viral infections, specifically when the inciting virus is respiratory syncytial virus (RSV), herpes simplex virus (HSV), varicella zoster virus (VZV), influenza virus, and parainfluenza virus type 3. (50) The most common nonrespiratory viral infections during neutropenia are due to HSV reactivation, with chemotherapyinduced immunosuppression or underlying malignancy increasing the likelihood of HSV reactivation. (51)(52) Severe mucositis can impair the mucosal barrier, leading to increased risk of bacterial infection, and can cause severe pain, reduction in nutritional intake, and cachexia. These potential complications may warrant prophylactic therapy to prevent HSV reactivation. Randomized, controlled studies show that prophylactic oral acyclovir significantly reduces the incidence of clinical HSV infection. (2)(52)(53) However, such prophylaxis has not been shown to reduce mucositisassociated bacteremia or mortality. (52)(54) To prevent HSV reactivation, prophylaxis with acyclovir or valacyclovir should be provided for all seropositive children who are likely to experience prolonged neutropenia. These include children who undergo autologous HSCT, those with AML, and those receiving induction chemotherapy for high-risk leukemia or reinduction therapy for relapsed leukemia (Table 1) . Prophylaxis should begin on day 1 for children undergoing autologous HSCT and continue to engraftment or until day 30, whichever is sooner. All others begin prophylaxis the day after completion of systemic chemotherapy and continue until resolution of neutropenia. Patients who are receiving antivirals for secondary HSV prophylaxis generally continue the agent until 3 months after completion of chemotherapy.
VZV reactivation is associated with significant morbidity in immunosuppressed children, including dermatomal rash, pain, and fever; however, the reactivation is rarely lifethreatening. Secondary prophylaxis for VZV is recommended for all patients with hematologic malignancies who have had an exposure using varicella zoster immune globulin or acyclovir during neutropenia and at least 30 days after HSCT. (2)(21) • Receiving a glucocorticoid dose equivalent to ‡20 mg of prednisone daily for 1 month or longer who also have another cause of immunocompromise (eg, certain hematologic malignancies or a second immunosuppressive drug)
• Receiving alemtuzumab (ie, for the treatment of acute leukemia) for a minimum of 2 months after completion of therapy or until the CD4 count is >200 cells/mL, whichever occurs later
• Receiving concomitant temozolomide and radiotherapy (for neuro-oncologic disease processes) until recovery of lymphopenia
• Allogeneic HSCT recipients after engraftment and for 3 months after completion of immunosuppressive therapy
• Select autologous HSCT recipients, including those who have an underlying hematologic malignancy, such as lymphoma, myeloma, or leukemia, especially when intensive treatment or conditioning regimens have included a purine analog (eg, fludarabine, cladribine) or highdose glucocorticoids
• Children receiving a purine analog, such as fludarabine, in combination with cyclophosphamide
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Vol. 37 No. 6 J U N E 2 0 1 6 Children with leukemia are more susceptible to influenza infection than their healthy peers because they experience prolonged symptoms and viral shedding, increased hospitalization, and prolonged bone marrow suppression. (55) Consistent with recent guidelines and CDC recommendations, yearly influenza vaccination with inactive vaccine is recommended for all patients age 6 months or older who are undergoing treatments for malignancy. Chemoprophylaxis with oseltamivir is recommended for all patients with known influenza exposure. (7) RSV is a major cause of infection and the primary cause of acute bronchiolitis in children. (56)(57) Immunocompromised patients may experience RSV-induced upper and lower respiratory tract infections, pneumonia, or even acute respiratory distress syndrome, resulting in a greater than 20% admission rate to the intensive care unit. (4) Due to the risks associated with RSV in immunocompromised infants, monthly prophylaxis with palivizumab during RSV season is suggested for children younger than age 24 months undergoing myelosuppressive chemotherapy, consistent with recommendations from the COG and AAP. (58) Hepatitis B surface antigen and core antibody should be assessed before HSCT and receipt of B-cell depleting therapies, such as rituximab and ofatumumab, due to risk of reactivation. (59) Patients who test positive for chronic hepatitis B infection should be closely monitored for the duration of therapy and several months after completion because reactivation has been reported after therapy discontinuation.
ANTIPARASITIC PROPHYLAXIS
Parasitic infections are usually not considered a risk for morbidity in children treated for cancer in the United States, but any child undergoing chemotherapy should have his or her lifetime travel history documented. Strongyloides stercoralis and S fuelleborni are intestinal nematodes that cause the disease strongyloidiasis. Immunocompromised persons are at risk for developing the life-threatening clinical manifestation of this infection called "hyperinfection syndrome" or disseminated strongyloidiasis. Strongyloides is endemic in tropical and subtropical regions. Unlike other nematodes, Strongyloides can complete its lifecycle without exiting the human host. Hence, infection may persist for many years. When the human host's immune system becomes compromised either by disease or immunosuppressive agents, multiple infective larvae can develop in what is known as (64) Clinical disease by the apicomplexan parasite Toxoplasma gondii can be the result of de novo infection of the child, transmission during pregnancy (congenital toxoplasmosis), transmission via a graft, or reactivation of latent infection in the context of immunodeficiency. Children should be tested for T gondii-specific immunoglobulin G before commencing immunosuppressive therapy (as defined in Table 2 ) to determine whether they are chronically infected with T gondii and at risk for reactivation of latent infection. (21) Cases of toxoplasmosis are uncommon, but if a child is seropositive, prophylaxis is recommended because of the benefit of preventing a potentially lifethreatening infection with a relatively well-tolerated regimen. (65)(66)(67)(68) Historically, treatment with pyrimethamine has been shown to be efficacious in patients who are immunocompromised as a result of chemotherapy. (69)(70) Because TMP-SMX protects against Toxoplasma reactivation disease in persons with AIDS, it is likely that children receiving TMP-SMX are effectively protected from Toxoplasma as well. (71)(72) To date, only relatively small studies have been performed, but the results appear to support this strategy. (73)(74)(75)(76) Patients and their families also should be advised to avoid the consumption of raw meat and to exercise extreme caution when handling pet feces (cats in particular).
VACCINATIONS
Chemotherapy and its associated immunosuppression often disrupt routine vaccination schedules in pediatric oncology patients, placing these children at further risk for infection. The 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host has addressed this issue and made recommendations on the administration of vaccinations for children who are immunocompromised as a result of chemotherapy. (77) Vaccines ideally should be administered before planned immunosuppression, although this is rarely possible, given the urgency to begin chemotherapy. Inactivated vaccines, including pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine (if >2 years), should be administered >2 weeks before immunosuppression, whereas live vaccines should be given >4 weeks before immunosuppression. Another method of protecting the immunocompromised patient is to provide "cocoon care," in which every household member is updated on inactivated and live vaccines (excluding oral polio vaccine), including influenza. The immunocompromised child should avoid contact with a household member if skin lesions erupt following vaccination with varicella or zoster vaccine.
Routine inactivated vaccines should be administered to children receiving maintenance chemotherapy according to the CDC schedule (although these do not count as valid vaccinations). The inactivated influenza vaccine should be administered annually to all patients equal to or greater than age 6 months undergoing chemotherapy, except patients receiving anti-B-cell antibodies or intensive chemotherapy (induction or consolidation chemotherapy) because it is unlikely the child will make an immunoprotective response to the vaccine. Live vaccines, including live attenuated influenza, the routine measles-mumpsrubella, and varicella-zoster vaccines, should not be administered to immunocompromised persons.
Standard vaccination according to the CDC schedule should be resumed 3 months after completion of chemotherapy or 6 months after receiving chemotherapy that includes anti-B-cell antibodies.
Because the data on whether children retain serologic immunity to routine childhood vaccines following systemic chemotherapy are limited and conflicting, there are no guidelines for revaccination or monitoring serologic immunity of children who have already completed the routine childhood vaccination schedule before chemotherapy. The 2013 IDSA guideline mentions that routine revaccination with a single dose of each vaccine antigen or serologic testing could be considered, although there is no statement on whether this should be done. At our institution, we recommend revaccination with 1 dose of all prior vaccinations that the child had received following completion of chemotherapy. Because measurement of titers is often not a reliable or sensitive test for immunoprotection, we choose to forgo serology testing to avoid confusion and provide a one-time revaccination as the most effective method of ensuring immunity.
